ES2071227T3 - Composicion para gotas para los ojos. - Google Patents

Composicion para gotas para los ojos.

Info

Publication number
ES2071227T3
ES2071227T3 ES91307275T ES91307275T ES2071227T3 ES 2071227 T3 ES2071227 T3 ES 2071227T3 ES 91307275 T ES91307275 T ES 91307275T ES 91307275 T ES91307275 T ES 91307275T ES 2071227 T3 ES2071227 T3 ES 2071227T3
Authority
ES
Spain
Prior art keywords
composition
eye drops
benzoxadine
tioxo
dihidro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91307275T
Other languages
English (en)
Spanish (es)
Inventor
Kazumichi Ushio
Yoshifumi Ikejiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2071227T3 publication Critical patent/ES2071227T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES91307275T 1990-08-13 1991-08-08 Composicion para gotas para los ojos. Expired - Lifetime ES2071227T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21482790 1990-08-13
JP16285491 1991-07-03

Publications (1)

Publication Number Publication Date
ES2071227T3 true ES2071227T3 (es) 1995-06-16

Family

ID=26488494

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91307275T Expired - Lifetime ES2071227T3 (es) 1990-08-13 1991-08-08 Composicion para gotas para los ojos.

Country Status (16)

Country Link
US (1) US5663170A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0472327B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2769253B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR920003971A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE121295T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU633754B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2048942A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69109021T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0472327T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2071227T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI97777C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU207950B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO177845C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT98643B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2068260C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW200402B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK143893A3 (en) * 1992-03-18 1994-05-11 Cooper Vision Pharmaceuticals Verapamil hci formulation and other opthalmic solutions with buffer system for ocular administration
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
WO1994010976A1 (en) * 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Polyvinyl alcohol/borate ophthalmic drug delivery system
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
AU7371894A (en) * 1993-07-28 1995-02-28 Insite Vision Incorporated Suspensions for delivery of medicament
EP0777415A4 (en) * 1994-07-11 1999-06-16 David W Pate COMPOSITIONS CONTAINING AN ANANDAMIDE ANALOG AND METHOD FOR TREATING INCREASED EYE PRESSURE USING IT
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
ATE215821T1 (de) * 1995-01-20 2002-04-15 Wakamoto Pharma Co Ltd Entzündungshemmende augentropfen
CN1087169C (zh) * 1995-01-20 2002-07-10 若素制药株式会社 抗炎症点眼剂
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2342797A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
HUP0201466A3 (en) * 1999-06-11 2003-04-28 Sankyo Co Ocular tension lowering composition for topical administration
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
ES2263623T3 (es) * 2000-06-19 2006-12-16 Santen Pharmaceutical Co., Ltd. Agentes antisepticos.
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
WO2006137433A1 (ja) * 2005-06-21 2006-12-28 Wakamoto Pharmaceutical Co., Ltd. レボカバスチンを可溶化させた水性薬剤
US20100069335A1 (en) * 2005-07-15 2010-03-18 Rajiv Bhushan Prevention and Treatment of Ophthalmic Complications of Diabetes
PT2832359T (pt) 2012-03-26 2019-01-29 Santen Pharmaceutical Co Ltd Colírio contendo diquafosol
TW202014194A (zh) * 2018-04-27 2020-04-16 美商歐樂根公司 抗微生物功效增強且毒性降低之亞氯酸鈉組成物
TW202133845A (zh) * 2019-11-21 2021-09-16 韓商三進製藥股份有限公司 用於預防或治療眼部疾病之眼用組合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602641B2 (en) * 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use

Also Published As

Publication number Publication date
US5663170A (en) 1997-09-02
NO177845C (no) 1995-12-06
CA2048942A1 (en) 1992-02-14
DE69109021D1 (de) 1995-05-24
FI913811A0 (fi) 1991-08-12
KR920003971A (ko) 1992-03-27
JPH05213757A (ja) 1993-08-24
PT98643A (pt) 1992-07-31
FI97777C (fi) 1997-02-25
PT98643B (pt) 1999-01-29
HUT61196A (en) 1992-12-28
FI913811L (fi) 1992-02-14
AU8170891A (en) 1992-02-20
NO913136L (no) 1992-02-14
EP0472327A1 (en) 1992-02-26
NO913136D0 (no) 1991-08-12
JP2769253B2 (ja) 1998-06-25
DE69109021T2 (de) 1995-09-21
NO177845B (no) 1995-08-28
RU2068260C1 (ru) 1996-10-27
EP0472327B1 (en) 1995-04-19
AU633754B2 (en) 1993-02-04
DK0472327T3 (da) 1995-05-08
ATE121295T1 (de) 1995-05-15
FI97777B (fi) 1996-11-15
HU912692D0 (en) 1992-01-28
HU207950B (en) 1993-07-28
TW200402B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-02-21

Similar Documents

Publication Publication Date Title
ES2071227T3 (es) Composicion para gotas para los ojos.
AU545023B2 (en) Optically active 1,4-dihydropyridine compound
ES2056071T3 (es) Triazolinonas substituidas.
ATE181656T1 (de) Intraoculares linsensystem
DE69225970D1 (de) Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
CY1350A (en) Improvements in or relating to 3-aryloxy-3-phenylpropylamines
FI931250A0 (fi) Sulfonamido- och sulfonamidokarbonyl-pyridin-2-karboxylsyraamider och deras pyridin-n-oxider, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
ES2051700T3 (es) Un proceso para la preparacion de un compuesto beta-lactama.
SE8404019L (sv) Oftalmiska antiinflammatoriska medel
SE8305864D0 (sv) Ogondroppar
BR9102016A (pt) Colheitadeira integral para cana-de-acucar
ES2118708T3 (es) Composiciones de piperidina y su preparacion y utilizacion.
ES2062215T3 (es) Derivados aminoalcoxibencenicos sustituidos.
ES262083Y (es) "cuerpos alargados que contienen elementos para telecomunicaciones con fibras opticas".
ES2083315B1 (es) Procedimiento para preparar compuestos de isoquinolina como agentes bloqueadores neuromusculares.
AR227031A1 (es) Esteres alquilicos del acido n'-(fenilsulfonil)-n-((1,-3,5-triazin o pirimidin)-2-il)carbamimidico y una composicion para el control de la vegetacion no deseada que los contiene
BR9205413A (pt) Processo para a preparação de (S)-cianoidrinas oticamente ativas.
ES2187534T3 (es) Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida.
ES2103575T3 (es) Procedimiento para la preparacion de 9-(2-hidroxi)-etoximetil-guanina.
AP8800109A0 (en) "Heterocyclic insecticides".
DE69116224D1 (de) Behandlung von intraokularem Druck mit einer synergischen Kombination
YU46914B (sh) Metoksimetilna jedinjenja
ES2163501T3 (es) Agente para la disminucion de la tension ocular.
ES8506661A1 (es) Procedimiento para la preparacion de un nuevo derivado de 2-tolil-morfolina util en terapeutica
EP0038003A3 (en) Antidepressant pyrrolylpiperidines

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 472327

Country of ref document: ES